References
- Mellor H, Parker PJ. The extended protein kinase C superfamily. Biochem J 1998;332:281–292.
- Alkan S, Huang Q, Ergin M, et al. Survival role of protein kinase C (PKC) in chronic lymphocytic leukemia and determination of isoform expression pattern and genes altered by PKC inhibition. Am J Hematol 2005;79:97–106.
- Barragan M, de Frias M, Iglesias-Serret D, et al. Regulation of Akt/PKB by phosphatidylinositol 3-kinase-dependent and -independent pathways in B-cell chronic lymphocytic leukemia cells: role of protein kinase C{beta}. J Leukoc Biol 2006;80:1473–1479.
- Kabir NN, Rönnstrand L, Kazi JU. Protein kinase C expression is deregulated in chronic lymphocytic leukemia. Leuk Lymphoma 2013;54:2288–2290.
- Abrams ST, Lakum T, Lin K, et al. B-cell receptor signaling in chronic lymphocytic leukemia cells is regulated by overexpressed active protein kinase CbetaII. Blood 2007;109:1193–1201.
- Ringshausen I, Schneller F, Bogner C, et al. Constitutively activated phosphatidylinositol-3 kinase (PI-3K) is involved in the defect of apoptosis in B-CLL: association with protein kinase Cdelta. Blood 2002;100:3741–3748.
- Perez-Chacon G, Vargas JA, Jorda J, et al. CD5 provides viability signals to B cells from a subset of B-CLL patients by a mechanism that involves PKC. Leuk Res 2007;31:183–193.
- Hubmann R, Duchler M, Schnabl S, et al. NOTCH2 links protein kinase C delta to the expression of CD23 in chronic lymphocytic leukaemia (CLL) cells. Br J Haematol 2010;148:868–878.
- zum Buschenfelde CM, Wagner M, Lutzny G, et al. Recruitment of PKC-betaII to lipid rafts mediates apoptosis-resistance in chronic lymphocytic leukemia expressing ZAP-70. Leukemia 2010;24:141–152.
- Lutzny G, Kocher T, Schmidt-Supprian M, et al. Protein kinase C-beta-dependent activation of NF-kappaB in stromal cells is indispensable for the survival of chronic lymphocytic leukemia B cells in vivo. Cancer Cell 2013;23:77–92.
- Furman RR, Byrd JC, Brown JR, et al. CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110{delta}, demonstrates clinical activity and pharmacodynamic effects in patients with relapsed or refractory chronic lymphocytic leukemia. Blood 2010;116(Suppl. 1): Abstract 55.
- Burger JA, O’Brien S, Fowler N, et al. The Bruton's tyrosine kinase inhibitor, PCI-32765, is well tolerated and demonstrates promising clinical activity in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL): an update on ongoing phase 1 studies. Blood 2010;116(Suppl. 1): Abstract 57.
- Byrd JC, Shinn C, Willis CR, et al. UCN-01 induces cytotoxicity toward human CLL cells through a p53-independent mechanism. Exp Hematol 2001;29:703–708.
- Ganeshaguru K, Wickremasinghe RG, Jones DT, et al. Actions of the selective protein kinase C inhibitor PKC412 on B-chronic lymphocytic leukemia cells in vitro. Haematologica 2002;87:167–176.
- Sato S, Fujita N, Tsuruo T. Interference with PDK1-Akt survival signaling pathway by UCN-01 (7-hydroxystaurosporine). Oncogene 2002;21:1727–1738.
- Virchis A, Ganeshaguru K, Hart S, et al. A novel treatment approach for low grade lymphoproliferative disorders using PKC412 (CGP41251), an inhibitor of protein kinase C. Hematol J 2002;3:131–136.
- Sedlacek HH. Mechanisms of action of flavopiridol. Crit Rev Oncol Hematol 2001;38:139–170.
- Ringshausen I, Oelsner M, Weick K, et al. Mechanisms of apoptosis-induction by rottlerin: therapeutic implications for B-CLL. Leukemia 2006;20:514–520.
- Forsyth CJ, Gomez D, Eliadis P, et al. Enzastaurin in patients with non-Hodgkin lymphomas: a multicenter, open-label, screening study. Blood 2009;114(Suppl. 1): Abstract 3719.